EA201992532A1 - Композиции и способ для лечения депрессии - Google Patents

Композиции и способ для лечения депрессии

Info

Publication number
EA201992532A1
EA201992532A1 EA201992532A EA201992532A EA201992532A1 EA 201992532 A1 EA201992532 A1 EA 201992532A1 EA 201992532 A EA201992532 A EA 201992532A EA 201992532 A EA201992532 A EA 201992532A EA 201992532 A1 EA201992532 A1 EA 201992532A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compositions
pramipexole
treating depression
antagonist
eliminate
Prior art date
Application number
EA201992532A
Other languages
English (en)
Inventor
Томас Н. Чейс
Кэтлин Э. Клэренс-Смит
Original Assignee
Чейс Терапьютикс Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Чейс Терапьютикс Корпорейшн filed Critical Чейс Терапьютикс Корпорейшн
Publication of EA201992532A1 publication Critical patent/EA201992532A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

В настоящем изобретении описана комбинация 5HT3-антагониста с прамипексолом для уменьшения или устранения нежелательных явлений, связанных с применением прамипексола, и для обеспечения применения высоких доз прамипексола, полезных для лечения депрессивных расстройств, таких как большое депрессивное расстройство.
EA201992532A 2017-04-24 2018-04-23 Композиции и способ для лечения депрессии EA201992532A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762489016P 2017-04-24 2017-04-24
PCT/US2018/028885 WO2018200387A1 (en) 2017-04-24 2018-04-23 Compositions and method for treating depression

Publications (1)

Publication Number Publication Date
EA201992532A1 true EA201992532A1 (ru) 2020-04-03

Family

ID=63919245

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992532A EA201992532A1 (ru) 2017-04-24 2018-04-23 Композиции и способ для лечения депрессии

Country Status (14)

Country Link
US (1) US20200375957A1 (ru)
EP (1) EP3615024A4 (ru)
JP (2) JP7397669B2 (ru)
KR (1) KR20200014289A (ru)
CN (1) CN110719778A (ru)
AU (1) AU2018258117A1 (ru)
BR (1) BR112019022175A2 (ru)
CA (1) CA3097332A1 (ru)
EA (1) EA201992532A1 (ru)
IL (1) IL270104B (ru)
MA (1) MA48477A (ru)
MX (2) MX2019012594A (ru)
TW (1) TW201841635A (ru)
WO (1) WO2018200387A1 (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021007744A (es) * 2018-12-27 2021-08-05 Chase Therapeutics Corp Composiciones de domperidona y metodos para tratar la depresion.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000074A1 (en) * 1991-06-26 1993-01-07 Sepracor, Inc. Method and compositions for treating emesis, nausea and other disorders using optically pure r(+) ondansetron
AU3675299A (en) * 1991-06-26 1999-08-19 Sepracor, Inc. Methods and compositions for treating emesis, nausa and other disorders using optically pure R(+) ondansetron
CA2301899C (en) * 1998-07-27 2008-11-18 Boehringer Ingelheim Pharma Kg Agent with an antidepressant activity
MY142204A (en) * 2002-07-25 2010-10-29 Pharmacia Corp Pramipexole once-daily dosage form
EP2026813A2 (en) 2006-05-09 2009-02-25 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP2334185A4 (en) * 2008-08-19 2011-09-21 Knopp Neurosciences Inc COMPOSITIONS AND METHODS FOR USE OF (R) -PRAMIPEXOL
KR101890317B1 (ko) 2010-12-16 2018-08-22 선오비온 파마슈티컬스 인코포레이티드 설하 필름
JOP20130213B1 (ar) * 2012-07-17 2021-08-17 Takeda Pharmaceuticals Co معارضات لمستقبلht3-5
AU2018243718A1 (en) * 2017-03-27 2019-11-07 Chase Therapeutics Corporation Compositions and methods for treating synucleinopathies

Also Published As

Publication number Publication date
TW201841635A (zh) 2018-12-01
JP2020517670A (ja) 2020-06-18
WO2018200387A1 (en) 2018-11-01
US20200375957A1 (en) 2020-12-03
JP7397669B2 (ja) 2023-12-13
AU2018258117A1 (en) 2019-12-12
CA3097332A1 (en) 2018-11-01
MX2019012594A (es) 2020-08-03
JP2024010018A (ja) 2024-01-23
MX2022013383A (es) 2022-11-30
EP3615024A4 (en) 2021-01-20
IL270104A (ru) 2019-12-31
MA48477A (fr) 2020-03-04
IL270104B (en) 2022-07-01
KR20200014289A (ko) 2020-02-10
CN110719778A (zh) 2020-01-21
BR112019022175A2 (pt) 2020-05-12
EP3615024A1 (en) 2020-03-04

Similar Documents

Publication Publication Date Title
EA201891910A1 (ru) Гетероарильные ингибиторы pad4
EA201991862A1 (ru) Композиции и способы, предназначенные для лечения гемоглобинопатий
EA201992878A1 (ru) Соединения для лечения болезни хантингтона
EA201892147A1 (ru) Бициклические соединения
PH12018500016A1 (en) Agents, uses and methods for the treatment of synucleinopathy
EA201890308A1 (ru) Замещенные азасоединения как ингибиторы irak-4
EA201691134A1 (ru) Новые ингибиторы глутаминазы
EA201891251A1 (ru) Бициклические ингибиторы pad4
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
EA201691872A1 (ru) Гетероциклические соединения для применения в лечении pi3k-гамма-опосредованных расстройств
EA201991720A1 (ru) Антитела к альфа-синуклеину и их применения
EA201992322A3 (ru) Соединения и композиции для лечения гематологических расстройств
EA201890157A1 (ru) Способы лечения эпителиоидноклеточных опухолей
TN2017000134A1 (en) 2-amino-3,5-difluoro-3,6-dimethyl-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors for treating alzheimer's disease
BR112019001039A2 (pt) composição para uso no tratamento de transtorno depressivo maior
EA201990257A1 (ru) Фракции плазмы крови в качестве лечения когнитивных расстройств, связанных со старением
EA201890185A1 (ru) Способы лечения опосредованных гепсидином нарушений
EA201990400A1 (ru) Соединения и композиции и их применение
EA201791030A1 (ru) 2-амино-5,5-дифтор-6-(фторметил)-6-фенил-3,4,5,6-тетрагидпропиридины в качестве ингибиторов bace1
EA201791348A1 (ru) Композиция орлистата и акарбозы с модифицированным высвобождением для лечения ожирения и связанных метаболических нарушений
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
EA201790327A1 (ru) Соединения замещенного пиперидина
UY37466A (es) N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa
MX2018012902A (es) Composiciones y métodos para el tratamiento de trastornos de almacenamiento lisosomal y trastornos caracterizados por disfunción lisosomal.
EA201891644A1 (ru) Антибактериальные соединения и их применение